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Abstract
Study Background: Vitamin D has wide-ranging effects on the immune system, and studies suggest that low serum vitamin
D levels are associated with worse clinical outcomes in HIV. Recent studies have identified an interaction between
antiretrovirals used to treat HIV and reduced serum vitamin D levels, but these studies have been done in North American
and European populations.
Methods: Using a prospective cohort study design nested in a multinational clinical trial, we examined the effect of three
combination antiretroviral (cART) regimens on serum vitamin D levels in 270 cART-naı¨ve, HIV-infected adults in nine diverse
countries, (Brazil, Haiti, Peru, Thailand, India, Malawi, South Africa, Zimbabwe and the United States). We evaluated the
change between baseline serum vitamin D levels and vitamin D levels 24 and 48 weeks after cART initiation.
Results: Serum vitamin D levels decreased significantly from baseline to 24 weeks among those randomized to efavirenz/
lamivudine/zidovudine (mean change: 27.94 [95% Confidence Interval (CI) 210.42, 25.54] ng/ml) and efavirenz/
emtricitabine/tenofovir-DF (mean change: 26.66 [95% CI 29.40, 23.92] ng/ml) when compared to those randomized to
atazanavir/emtricitabine/didanosine-EC (mean change: 22.29 [95% CI –4.83, 0.25] ng/ml). Vitamin D levels did not change
significantly between week 24 and 48. Other factors that significantly affected serum vitamin D change included country
(p,0.001), season (p,0.001) and baseline vitamin D level (p,0.001).
Conclusion: Efavirenz-containing cART regimens adversely affected vitamin D levels in patients from economically,
geographically and racially diverse resource-limited settings. This effect was most pronounced early after cART initiation.
Research is needed to define the role of Vitamin D supplementation in HIV care.
Citation: Havers FP, Detrick B, Cardoso SW, Berendes S, Lama JR, et al. (2014) Change in Vitamin D Levels Occurs Early after Antiretroviral Therapy Initiation and
Depends on Treatment Regimen in Resource-Limited Settings. PLoS ONE 9(4): e95164. doi:10.1371/journal.pone.0095164
Editor: Claire Thorne, UCL Institute of Child Health, University College London, United Kingdom
Received October 15, 2013; Accepted March 24, 2014; Published April 21, 2014
This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for
any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.
Funding: This work was supported by the AIDS Clinical Trials Group and was funded by the US National Institute of Allergy and Infectious Diseases [AI68636,
AI069450] and by additional grants from the US National Institutes of Health [R01 AI45462 to AG and T32 AI007291 to FH]. This research was also supported in
part by Boehringer-Ingelheim, Bristol-Myers Squibb, Gilead Sciences, and GlaxoSmithKline. The funders had no role in study design, data collection and analysis,
decision to publish, or preparation of the manuscript.
Competing Interests: The authors have the following interests: This research was supported in part by Boehringer-Ingelheim, Bristol-Myers Squibb, Gilead
Sciences, and GlaxoSmithKline. There are no patents, products in development or marketed products to declare. This does not alter the authors’ adherence to all
the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.
* E-mail: fhavers@cdc.gov (FH); agupta25@jhmi.edu (AG)
" Membership of the ACTG A5175 PEARLS study and NWCS 319 Study Teams is provided in the Acknowledgments.
Introduction
Vitamin D has well-known regulatory functions in calcium
metabolism, but is also increasingly recognized as an immune
modulator [1]. It regulates pathways involved in killing intracel-
lular pathogens [2], and modulates T cells, cytokines, and
dendritic cells [3–6]. Given these wide-ranging effects, vitamin D
deficiency may lead to defects in both innate and adaptive immune
defenses.
Inadequate vitamin D (defined here as serum 25(OH) vitamin D
level ,32 ng/ml) is widespread among HIV-infected persons,
with prevalence estimates ranging from 29 to 89 percent in
European and US HIV-infected populations [7–12]. Several
studies have suggested that inadequate vitamin D levels are
associated with worse clinical outcomes [9,13–15]. Specific
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antiretroviral medications, including efavirenz and zidovudine,
have been associated with lower serum vitamin D levels and may
exacerbate this problem [16–20].
Studies examining the impact of antiretroviral medications on
vitamin D have been done in North American and European
HIV-infected populations. Genetics influence vitamin D levels, as
do factors affecting UV light exposure and absorption, such as skin
pigmentation, cultural practices, season and latitude [21–23]. In
addition, more than 90% of HIV-infected people live in resource-
limited settings (RLS), where the prevalence of vitamin deficien-
cies, including vitamin D deficiency, is high [24,25]. Given the
ongoing scale-up of antiretroviral therapy in RLS, understanding
the impact of combination antiretroviral (cART) initiation on
vitamin D levels in RLS is essential. We examined the effect of
cART initiation with three different regimens in nine geograph-
ically, economically and racially diverse countries.
Methods
Study Population
The study population was a nested cohort of the Prospective
Evaluation of Antiretrovirals in Resource Limited Settings
(PEARLS) trial (Adult AIDS Clinical Trials Group (ACTG)
A5175, NCT00084136), an open-label, randomized clinical trial
of three cART regimens. The parent study population has been
described in detail elsewhere [26], but in brief, participants were
1571 adults, 18 years or older from 9 countries (Brazil, Haiti, Peru,
Thailand, India, Malawi, South Africa, Zimbabwe and the United
States) on four continents, primarily RLS. They were HIV-
infected with a CD4 count less than 300 cells/mm3, antiretroviral
naı¨ve, not pregnant and were excluded if they were acutely ill or
had acute serious co-morbidities or laboratory abnormalities.
The study was approved by the institutional review boards and
ethics committees at participating institutions, with written,
informed consent obtained from all participants.
Design
Subjects were randomly assigned 1:1:1 to one of three open-
label regimens. Arm A was efavirenz 600 mg daily plus
lamivudine-zidovudine 150 mg/300 mg twice daily; Arm B was
atazanavir 400 mg, didanosine-EC 400 mg and emtricitabine
200 mg once daily; Arm C was efavirenz 600 mg plus emtricita-
bine-tenofovir-DF 200 mg/300 mg once daily. This sub-study
used a pre-specified subcohort of 270 participants. Thirty
participants, stratified by treatment arm, were randomly chosen
from each country.
Laboratory Methods
Serum specimens were collected before or at entry to the
PEARLS study and were stored at 270 Celsius. Serum vitamin D
levels were measured at a single Clinical Laboratory Improvement
Amendments (CLIA)-certified laboratory at the Johns Hopkins
Hospital using the chemiluminescence immunoassay (DiaSorin,
Stillwater, MN), which measures both vitamin D2 and D3 and is
reported as a total serum 25(OH) vitamin D level [27].
Definitions and Measurement
Vitamin D insufficiency was defined as 25(OH) vitamin D ,
32 ng/ml and deficiency as ,20 ng/ml [28]. Race was defined as
black, white, Asian, other, or more than one race. Seasons were
defined depending on the hemisphere of the country. For northern
hemisphere countries, spring was defined as months 3–5 (southern
hemisphere: months 9–11); summer, months 6–8 (southern
hemisphere: months 12–2); autumn, months 9–11 (southern
hemisphere: months 3–5), and winter, months 12–2 (southern
hemisphere: months 6–8). Vitamin D levels were expected to be
lower in winter and spring when compared to summer and
autumn [8,9,29]. Subsequently, in this analysis, winter and spring
were defined as ‘‘low vitamin D months’’ while the reciprocal
months were defined as ‘‘high vitamin D months.’’ Normal weight
range was defined as body mass index (BMI) 18–25 kg/m2, with
overweight .25 kg/m2.
Outcomes
The primary outcome was the change in serum 25-OH vitamin
D level between baseline and 24 weeks. The change between week
24 and 48-week was also analyzed. However since analyses
indicated that the largest change in Vitamin D occurred in the first
24 weeks post cART initiation (Figure 1), predictor models
described below only used the change between week 0 and week
24.
Statistical Analysis
Background characteristics among treatment groups were
assessed using Pearson’s chi-squared test. Mean change in vitamin
D levels from cART initiation to 24 weeks after cART initiation
and 95% confidence intervals, were estimated using linear
regression models. First, univariate models were examined. This
analysis was nested in a randomized controlled trial, which
theoretically should control for measured and unmeasured
confounder at baseline. However, some variation between groups
in confounding factors will inevitably occur by chance, and a
multivariate model that controls for additional confounders can
also be used; it can increase the precision of the estimate of the
association between exposure and outcome, as well as provide
additional information about factors beyond treatment regimens
that may affect the change in vitamin D level after cART
initiation. In choosing covariates for the multivariate linear
regression models, in addition to treatment group, all covariates
that had been shown to influence baseline vitamin D levels in this
study population [29] were initially included in the model. These
included HIV viral load, race, country, season of baseline sample,
and BMI. Sex, age, baseline vitamin D level, baseline CD4 count,
baseline hemoglobin, baseline creatinine clearance, and baseline
albumin level were also included in the multiple linear regression
models because there was biologic plausibility of the effect of the
variable on the change in vitamin D level or the covariate had face
validity as a potential confounder. Models were evaluated using
the Akaike information criterion (AIC) to determine the most
parsimonious model.
In all analyses, intention-to-treat principle was followed. The a
priori significance level was set at alpha = 0.05 for a two-sided
significance test. Data were analyzed using Stata/IC version 12.1.
Results
A total of 220 (81%) of 270 randomly selected persons had both
week 0 and week 24 vitamin D measurements, 222 (82%) had
week 0 and week 48, and 205 (76%) had weeks 0, 24, and 48. Fifty
subjects, most from a study site in India, were excluded for either
missing baseline or 24 week data. Besides country and race, those
with missing data were significantly more likely to be underweight
than other subjects, but otherwise did not differ significantly from
the rest of the sample (data not shown). Four participants who died
before 24 weeks were excluded.
Baseline age, sex, race, BMI, and baseline CD4 count, HIV
viral load, and serum vitamin D levels (median 32 ng/ml; IQR
25–39 ng/ml) were similar between treatment arm groups
Vitamin D Levels after Antiretroviral Initiation
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(Table 1). 52% of the patients had serum vitamin D levels $
32 ng/ml (adequate). In contrast, 48% of patients had serum
vitamin D levels ,32 ng/ml (insufficient) and 14% had ,20 ng/
ml (deficient).
Change in Vitamin D Levels from Baseline to Week 24
and Week 48 Post cART Initiation
Vitamin D levels decreased after cART initiation, with the
greatest decrease in the first 24 weeks (Table 2, Figure 1). In
univariate analysis comparing change in vitamin D in treatment
Table 1. Study population characteristics by treatment arm.
Characteristic Treatment Group
All A: EFV+3TC/ZDV
B: ATV + DDI +
FTC C: EFV + TDF/FTC p-value
All, no. 220 79 76 65
Sex, no. (%) Male 106 (48) 41 (52) 38 (50) 27 (42) 0.43
Female 114 (52) 38 (48) 38 (50) 38 (58)
Age–years, median (IQR) 35 (30–42) 35 (30–40) 35 (30–42) 34 (30–42) 0.88
Country, no. (%) Brazil 29 (13) 12 (15) 9 (12) 8 (12) 0.58
Haiti 27 (12) 11 (14) 11 (14) 5 (7)
India 5 (2) 2 (3) 2 (3) 1 (2)
Malawi 24 (11) 11 (14) 7 (9) 6 (9)
Peru 28 (13) 10 (13) 5 (7) 13 (20)
South Africa 26 (12) 8 (10) 10 (13) 6 (9)
Thailand 26 (12) 7 (9) 10 (13) 11 (16)
United States 27 (13) 6 (8) 10 (13) 6 (9)
Zimbabwe 28 (13) 12 (15) 10 (12) 7 (10)
Race, no. (%) White 27 (12) 5 (6) 13 (17) 9 (14) 0.46
Black 127 (57) 53 (67) 44 (58) 30 (46)
Asian 32 (15) 11 (11) 12 (16) 11 (17)
Other* 33 (16) 12 (15) 7 (9) 14 (22)
BMI, no. (%) BMI ,18.5 kg/m2 16 (7) 6 (8) 6 (8) 4 (6) 0.87
BMI 18–25 kg/m2 143 (65) 55 (70) 46 (60) 42 (65)
BMI $25 kg/m2 61 (28) 18 (22) 24 (32) 19 (29)
Prior AIDS diagnosis, no. (%) 16 (7) 6 (8) 6 (8) 4 (6) 0.92
Baseline CD4 count–cells/ml, median (IQR) 180 (87–231) 168 (64–245) 193 (126–241) 163 (82–216) 0.76
Baseline viral load–log10copies/ml, median (IQR) 5.07
(4.61–5.48)
5.07 (4.63–5.48) 5.04 (4.55–5.46) 5.07 (4.64–5.57) 0.93
Baseline vitamin D
category, no. (%)
Severely deficient (#10 ng/ml) 3 (1) 2 (3) 1 (1) 0 (0) 0.77
Deficient (10–20 ng/ml) 28 (13) 8 (10) 9 (12) 11 (17)
Insufficient (20–32 ng/ml) 74 (34) 28 (35) 26 (34) 20 (31)
Adequate ($32 ng/ml) 115 (52) 41 (52) 40 (53) 34 (52)
Baseline vitamin D–ng/ml, median (IQR) 32 (25–39) 32 (25–39) 32 (25–39) 32 (25–43) 0.89
*The majority of those reporting race as ‘‘Other’’ were Mestizo from Peru, Brazil and Haiti. Abbreviations: EFV, efavirenz; 3TC, lamivudine; ZDV, zidovudine; ATV,
atazanavir; DDI, didanosine-EC; FTC, emtricitabine; TDF, tenofovir-DF; IQR, interquartile range; BMI, body mass index (kg/m2).
doi:10.1371/journal.pone.0095164.t001
Table 2. Mean change by treatment arm in serum vitamin D, 0 to 24 weeks and 24 to 48 weeks.
Mean change, Vitamin D
ng/ml (CI) A: EFV+3TC/ZDV B: ATV+DDI +FTC C: EFV+TDF/FTC
A=B
p-value
B=C
p-value
A=C
p-value
0 to 24 week (n = 220) –7.9 (–10.4, 25.5) –2.3 (–4.8, 0.3) –6.7 (–9.4, 23.9) 0.002 0.022 0.50
24 to 48 week (n = 211) –0.22 (–2.4, 2.0) 1.5 (–0.5, 3.5) 0.63 (–2.1, 3.3) 0.24 0.59 0.62
Abbreviations: EFV, efavirenz; 3TC, lamivudine; ZDV, zidovudine; ATV, atazanavir; DDI, didanosine-EC; FTC, emtricitabine; TDF, tenofovir-DF; IQR, interquartile range; BMI,
body mass index (kg/m2).
doi:10.1371/journal.pone.0095164.t002
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arms from 0 to 24 weeks, levels declined significantly in both
efavirenz-based arms (Arm A, mean change 27.94 ng/ml (95%
confidence interval (CI) 210.42 to 25.54); Arm C, mean change
26.66 ng/ml (95% CI 29.40 to 23.92). The level in Arm B, the
atazanavir-based arm, also decreased between 0 and 24 weeks, but
this was not significant (mean change 22.30 ng/ml; 95% CI 2
4.86 to 0.25). There was no difference between the change in
Arms A and C (p = 0.498), though arms A and C both differed
from Arm B (p = 0.002 and p = 0.022 respectively). There was no
significant change between overall mean Vitamin D levels at week
24 and week 48 (p = 0.34). There was also no significant between
the specific Arms (Arm A vs Arm B, p = 0.24; Arm B vs C,
p = 0.59; and Arm A vs C, p = 0.62); Arm A, mean change 2
0.22 ng/ml (95% CI 22.41 to 21.96); Arm B, mean change
1.52 ng/ml (95% CI 20.47 to 3.51); Arm C, mean change
0.63 ng/ml (95% CI 22.06 to 3.32) (Table 2).
Independent Factors Associated with Change in Vitamin
D Levels between Week 0 and Week 24
Multivariate analysis revealed that besides treatment arm, only
country (p,0.001), baseline vitamin D (p,0.001), and season of
baseline sample (p,0.001) were significantly associated with
change in vitamin D level between week 0 and week 24. After
adjusting for these factors, the relationship between treatment
arms A and B (p,0.001) and between C and B was unchanged
(p = 0.023).
In the initial model (Model A, Table 3), which was the
saturated model with all possible confounders, country, baseline
vitamin D and season of baseline sample, and treatment arm were
the only covariates with a significant association with change in
vitamin D level. There was strong co-linearity between race and
country, and based on results from Model A, country appeared to
have a stronger relationship with change in vitamin D compared
with race. Although both variables predicted baseline vitamin D
status, when examining change in vitamin D level, race had no
significant association once controlling for country (Wald p = 0.34)
(Model A, Table 3). Race was thus excluded from Model B
(Table 3), as were baseline hemoglobin, albumin and creatinine
clearance; in analyses in which these three latter variables were
evaluated separately and together, none appeared to contribute to
the model (Wald test p = 0.25). In Model B, after adjusting for
potential factors that potentially affect change in vitamin D level
(baseline vitamin D, age, sex, CD4, viral load, country, season
BMI), the relationship between the effect of the treatment arms
was similar. It also did not change substantially in the most
parsimonious model by AIC (Model C, Table 3), which
excluded all variables except treatment arm, baseline season,
baseline vitamin D level and country.
When the analyses were repeated with percent change from
baseline vitamin D level to 24-week vitamin D level, rather than
absolute change in vitamin D level, there were no substantive
differences in the results. Those with the highest baseline vitamin
D levels showed the greatest percent decrease, and the effect of
treatment regimen on change in vitamin D was similar when
percent change was examined rather than absolute change (data
not shown).
Country did affect the change in vitamin D level (Wald p,
0.001). Declines in vitamin D level were statistically significantly
greater in India and Peru when compared with the reference
country Brazil (p = 0.043 and p = 0.025 respectively), with those in
Zimbabwe having a relative increase in vitamin D level when
compared to Brazil (p = 0.004). Because of the complex interaction
of race and geography, and previous findings that differences in
skin pigmentation and genetic polymorphisms associated with
specific racial groups affect vitamin D metabolism, further
sensitivity analyses of racial groups was performed. Blacks in the
Americas (United States, Haiti and Brazil) had a greater decline in
vitamin D level when compared to blacks from Africa (Zimbabwe,
Malawi, and South Africa) (difference in mean change 25.1 ng/
ml; 95% CI 28.3 to 21.9) (Figure 2). When US blacks were
compared to all non-US blacks, there was a larger decrease in
vitamin D level at 24 weeks (difference in mean change 29.42;
95% CI 215.2 to 23.6) ng/ml). There was no significant
interaction between treatment arm and any racial group.
Discussion
Our study demonstrated that serum vitamin D levels decline
significantly in the first 24 weeks of initiating two different
efavirenz-based regimens, but not an atazanavir-based regimen.
Furthermore, after this initial change, serum vitamin D levels did
not change significantly between week 24 and week 48, indicating
that most of the effect on vitamin D occurs soon after antiretroviral
treatment initiation. These findings were consistent in treatment-
Figure 1. Mean Vitamin D Level by Treatment Group. Abbreviations: EFV, efavirenz; 3TC, lamivudine; ZDV, zidovudine; ATV, atazanavir; DDI,
didanosine-EC; FTC, emtricitabine; TDF, tenofovir-DF.
doi:10.1371/journal.pone.0095164.g001
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naı¨ve patients across diverse racial and geographic settings,
including resource-limited settings.
A number of previous studies have shown an association
between efavirenz and increased risk of vitamin D deficiency,
although most have been done in North American or European
settings [17,19,20,30]. These include a French cohort study that
showed that efavirenz, but not other antiretroviral medications,
was associated with vitamin D deficiency [30]. Another study
among 87 HIV patients in the United States who had baseline
vitamin D levels measured prior to antiretroviral initiation and
again 6 to 12 months later found that those given efavirenz-
containing regimen had a significantly greater drop than the non-
efavirenz group [20]; a Swiss cohort found that although cART
exposure in general had no significant impact on vitamin D levels,
NNRTI use was associated with lower levels [8]. These findings
were confirmed by a cross-sectional study conducted in London,
where efavirenz use was found to be associated with severe vitamin
D deficiency (,10 ng/ml) [19]. Although efavirenz has been the
antiretroviral drug most implicated in lowering vitamin D levels,
cART regimens contain multiple medications, and it is possible
that the other medications besides efavirenz had an effect on
vitamin D. Both efavirenz and zidovudine were associated with
vitamin D deficiency in the MONET trial, which was conducted
among European HIV-positive adults on cART with HIV RNA,
50 copies/ml, on a wide variety of regimens at baseline. In
addition, when study participants were changed to a regimen with
boosted darunavir, vitamin D levels rose, with the greatest increase
in vitamin D levels was among those who changed from efavirenz
or zidovudine [17]. However, in our study, zidovudine did not
appear to be significantly associated with change in vitamin D
level, as there was no significant difference between the arms that
contained efavirenz plus lamivudine-zidovudine when compared
to efavirenz plus emtricitabine-tenofovir-DF.
The mechanism of efavirenz’s effect on vitamin D has been
linked to induction of cytochrome P450, and the effect this has on
several enzymes in this family. These include CYP24, which
converts both 25(OH) vitamin D and the active form of vitamin D,
1,25(OH)2 vitamin D, to their inactive metabolites. Efavirenz also
reduces the expression of cytochrome CYP2R1, which hydroxyl-
ates D3 and D2, necessary for vitamin D activation [31,32].
However, it is unclear why vitamin D levels appear to drop most
sharply in the first six months after cART initiation, but then
appear to have a much smaller decline, if any, between 24 and 48
weeks. We postulate that there may be an initial induction of
cytochrome P450 enzymes by efavirenz and then stabilization
after maximal effect, and this occurs most prominently within the
first 24 weeks. Alternatively it is possible that while there are early
changes in the vitamin D protein binding [33] or regulation after
cART initiation, compensatory mechanisms stabilize vitamin D
levels over the long term, although this has yet to be clearly
elucidated.
A number of factors have been shown to affect baseline vitamin
D levels, such as BMI, non-white race, viral load, season of
sample, and country [11,18,29]. Geographical factors such as
latitude and altitude, as well as environmental factors such air
pollution, can also affect vitamin D levels; cultural practices such
avoiding sun exposure can also have an impact [23]. The relatively
high median vitamin D values in this study population compared
to other cohorts of HIV-infected individuals likely reflects the
geographic, economic, racial and cultural diversity of this study
population. In addition, we chose to include both deficiency and
insufficiency together using the recommended pre-specified cut-off
of ,32 ng/ml for the Diasorin assay because, although severe
vitamin D deficiency was relatively uncommon in our study,
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vitamin D insufficiency was relatively common in all country-race
groups and has widespread clinical relevance [28].
In this study, those who started with the highest vitamin D levels
had the greatest declines after cART initiation, examined both by
absolute change in vitamin D levels and percent change from
baseline to 24 weeks. However, once baseline vitamin D level is
controlled for, most of these other factors did not appear to
influence the decrease in vitamin D that occurs after cART
initiation. Country and season of sample were the exceptions in
this analysis. Country appeared to have a significant impact on the
change in vitamin D, although a clear pattern was not readily
apparent. A complex pattern of factors such as nutrition, racial
composition, latitude, elevation, and culture potentially affect the
role that country plays on change in vitamin D after cART
initiation. Seasonality also affects vitamin D status; those with
baseline samples drawn in summer and autumn (‘‘high vitamin D’’
seasons), and thus with 24-week samples drawn in fall or winter
(‘‘low vitamin D’’ seasons), experienced a greater drop in the six
months after cART initiation than those with a reciprocal change
from ‘‘low’’ to ‘‘high’’ vitamin D seasons. However, the effect of
treatment arm on change in vitamin D remained robust after
controlling for season and country.
Our study had some limitations. Subjects were excluded if they
had any acute illness or major lab abnormality. Thus, the clinical
trial population may be healthier than patients in routine HIV
care programs in comparable RLS. Our study was limited to three
specific anti-retroviral regimens. However, atazanavir and efavir-
enz-containing combinations are commonly used globally. In
addition, we did not have complete documentation on use of
vitamin D supplementation; however vitamin D supplementation
during the study conduct was reportedly very low in RLS. Patients
were excluded from analysis if they were missing either baseline or
24-week vitamin D data. However, apart from country, race, and
body mass index, the excluded patients did not significantly differ
from the analytic sample, and the missing data would not be
expected to bias our study results. In addition, we examined the
results based on an intention-to-treat model. A limited number of
patients switched regimens or discontinued cART after initiation
[26], but we did not have enough data or a large enough sample
size with vitamin D samples to exam the effect of stopping
antiretroviral medications on vitamin D levels.
Conclusions
Patients initiating two efavirenz-based cART regimens had a
significant early decline in their vitamin D levels when compared
to those initiating an atazanavir-based regimen. Further studies
are needed to explore whether early cART-related declines in
vitamin D level are clinically significant, what the long-term effects
may be, and whether vitamin D supplementation has any role.
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